1 |
Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Mol Imaging 2005;32:601-14
DOI
|
2 |
Smith JA, Myburgh JA, Neirinckx RD. Specific inactivation of sensitized lymphocytes in vitro using antigens labelled with astatine-211. Clin Exp Immunol 1973;14:107-16
|
3 |
Lambrecht RM, Mirzadeh S. Cyclotron isotopes and radiopharmcauticals-XXXV. Astatine-211. Int J Appl Radiat Isot 1985;36:443-50
DOI
ScienceOn
|
4 |
Lebeda O, Jiran R, Ralis J, Stursa J. A new internal target system for production of on the cyclotron U-120U. Appl Radiat Isot 2005;63:49-53
DOI
ScienceOn
|
5 |
McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25:1342-51
|
6 |
Melville G, Liu SF, Allen BJ. A theoretical model for the production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226. Appl Radiat Isot 2006;64:979-88
DOI
ScienceOn
|
7 |
Geerling MW. Radionuclides for radioimmunotherapy: criteria for selection. Int J Biol Markers 1993;8:180-6
DOI
|
8 |
Sgouros G, Erdi YE, Humm JL, Mehta B, McDevitt MR, Finn RD, et al. Pharmacokinetics and dosimetry of an alpha aprticle emitter labeled anti-CD33 antibody ([Bi-213]HuM195) in patients with leukemia. J Nucl Med 1999;40:1935-46
|
9 |
Atcher RW, Friedman AM, Huizenga JR, Spencer RP. A radionuclide generator for the production of Pb-211 and its daughters. J Radioanal Nucl Chem 1989;135:215-21
DOI
|
10 |
Allen BJ, Blagojevic N. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149. Nucl Med Commun 1996;17:40-7
DOI
ScienceOn
|
11 |
Goozee G, Allen BJ, Imam SK. Tandem accelerator production of Tb-149 for targeted cancer therapy, AINSE Radiation Science Conference 'RADIATION'96'
|
12 |
Buchegger F, Perillo-Adamer F, Dupertuis YM, Delaloye AB. Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging 2006;11:1352-63
|
13 |
Johnson EI, Turkington TG, Jaszezak RJ, Gilland DR, Vaidyanathan G, Greer KL, et al. Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl Med Biol 1995;22:45-54
DOI
ScienceOn
|
14 |
Geerling MW Sr, Kaspersen FM, Apostolidis C. The feasibility of Ac-225 as a source of in RIT. Nucl Med Commun 1993;14:121-5
DOI
|
15 |
Larsen RH, Wieland BW, Zalutsky MR. Evaluation of an internal cyclotron target for the production of via the reaction. Appl Radiat Isot 1996;47:135-43
DOI
ScienceOn
|
16 |
Sgouros G, Humm JL, McDevitt MR, Kennedy J, Schumaker R, Larson SM, et al. Bismuth-213 imaging: preclinical characterization of an alpha-particle emitting radionuclide. J Nucl Med 1996;37: 78-80
|
17 |
Apostolidis C, Molinet R, McGinley J, Abbas K, Mollenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot 2005;62:383-7
DOI
ScienceOn
|
18 |
Groppi F, Bonardi ML, Birattari C, Menapace E, Abbas K, Holzwarth U, et al. Optimasation study of -cyclotron production of At-211/Po-211g for high-LET metabolic radiotherapy purposes. Appl Radiat Isot 2005;63:621-31
DOI
ScienceOn
|
19 |
Boll RA, Malkemus D, Mirzadeh S. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiat Isot 2005;62:667-79
DOI
ScienceOn
|
20 |
Hassfjell S, Brechbiel MW. The development of the -particle emitting radionuclides , and their decay chain related radionuclides, for therapeutic applications. Chem Rev 2001;101: 2019-36
DOI
ScienceOn
|
21 |
Nikula TK, McDevitt MR, Finn RD, Chuanchu W, Kozak RW, Garmestani K, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 1999;40:166-76
|
22 |
Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AEI. J Nucl Med 1997;38: 1944-50
|
23 |
Humm JL A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys 1987;13:1767-73
DOI
ScienceOn
|
24 |
Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha-particles: part III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res 1991;128:204-9
DOI
|
25 |
Zalutsky MR, Zhao XG, Alston KL, et al. High-level production of alpha-particle-emitting 211At and preparation of 211At-labeled antibodies for clinical use. J Nucl Med 2001;42:1508-15
|
26 |
Wilbur DS. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody Immunoconj Radiopharm 1991;4: 85-97
|
27 |
Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted -particle therapy. J Nucl Med 2005;46:199S-204S
|
28 |
Mausner LF, Straub RE, Srivastava SC. The 'in vivo' generator for radioimmunotherapy. J Lab Comp Radiopharm 1989;26:177-8
DOI
|
29 |
Atcher RN, Friedman AM, Hines JJ. An improved generator for the production of Bi-212 and Bi-212 from Ra-224. Appl Radiat Isot 1988;39:283-6
DOI
|
30 |
Atcher RW, Hines JJ, Friedman AM. A remote system for the separation of Th-228 and Ra-224. J Radioanal Nucl Chem 1987;117:155-62
DOI
|
31 |
Spivakov BY, Stoyanov ES, Gribov LA, Zoltov YA. Raman laser spectroscopic studies of bismuth(III) halide complexes in aqueous solutions. J Inorg Nucl Chem 1979;41:453-5
DOI
ScienceOn
|
32 |
Henriksen G, Schoultz BW, Michaelsen TE, Bruland OS, Larsen RH. Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl Med Biol 2004;31:441-9
DOI
ScienceOn
|
33 |
Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005;46:4S-12S
|
34 |
Imam SK. Advancements in cancer therapy with alpha-emitters: A review. Int J Radiation Oncology Biol Phys 2001;51:271-8
|
35 |
Zalutsky MR, Narula AS. Astatination of protein using an N-succimidyl tri-n-butylstannyl benzoate intermediate. Appl Radiat Isot 1988;39:227-32
DOI
ScienceOn
|